Re-test your knowledge
Re-test your knowledge
Summary
Now that you have completed Module 1 Patient identification and management, you should have a better understanding of how chronic insomnia is defined, differentiating chronic insomnia from other sleep-related conditions and know how to diagnose and treat the condition. To test your knowledge, answer the questions below and see how your score has improved.
Ready for the next module?
Sleep mechanisms and QUVIVIQ™ action
CBTi: cognitive behavioural therapy for insomnia; ICD-11: International Classification of Diseases 11th Revision; NICE: National Institute for Health and Care Excellence
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.8
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- World Health Organization (WHO). International statistical classification of diseases and related health problems (ICD) 11th revision. Available at: icd.who.int. Accessed August 2025
- National Institute for Health and Care Excellence (NICE). NICE guideline 202. Obstructive sleep apnoea/ hypopnoea syndrome and obesity hypoventilation syndrome in over 16s, 20 August 2021. Available at: nice.org.uk. Accessed August 2025
- Sleep Foundation. At-home sleep study. Available at: sleepfoundation.org. Accessed August 2025
- Morin C M, Benca R. Chronic insomnia. Lancet 2012;379(9821):1129-1141
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia, May 2025. Available at: cks.nice.org.uk. Accessed August 2025
- Wilson S, Anderson K et al. British Association for Psychopharmacology consensus statement on evidence‑based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol 2019;33(8):923-947
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 922. Daridorexant for treating long‑term insomnia, 18 November 2023. Available at: nice.org.uk. Accessed August 2025
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
© NICE 2021. Obstructive sleep apnoea/ hypopnoea syndrome and obesity hypoventilation syndrome in over 16s. Available from www.nice.org.uk/guidance/ng202. All rights reserved. Subject to Notice of rights.
© NICE 2023. Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/TA922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00653 | Date of preparation: September 2025
